Skip to content
POM-V Prescription Required Companion Animal

Nobivac KC Nasal Drops, Lyophilisate and Solvent for Suspension for Dogs

Active ingredients: Bordetella bronchiseptica, Canine parainfluenza virus

Form

Drops

Species

Dogs

Manufacturer

Intervet International B.V.

VMD MA No.

06376/3014

What it's used for

bronchiseptica and canine parainfluenza virus and to reduce shedding of canine parainfluenza virus. Onset of immunity: for Bordetella bronchiseptica: 72 ho...

Full indications, dosage and side effects ↓
View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Bordetella bronchiseptica +...

  1. 1

    Ask your vet for a written prescription

    They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.

  2. 2

    Fill it at a registered online retailer

    The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Nobivac KC Nasal Drops, Lyophilisate and Solvent for Suspension for Dogs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

bronchiseptica and canine parainfluenza virus and to reduce shedding of canine
parainfluenza virus.
Onset of immunity: for Bordetella bronchiseptica: 72 hours after vaccination;
for canine parainfluenza virus: 3 weeks after vaccination.
Duration of immunity: 1 year.
Allow the sterile solvent provided to reach room temperature (15 °C – 25 °C).
Aseptically reconstitute the lyophilisate with the solvent. Shake the vial well after
addition of the solvent. Withdraw the vaccine into the syringe, remove the needle and
administer 0.4 ml directly from the tip of the syringe into one nostril.
The reconstituted vaccine is an off-white or yellowish coloured suspension.
Vaccination scheme:
Dogs should be at least 3 weeks of age. When this vaccine is concurrently
administered (i.e. not mixed) with another vaccine of the Nobivac series as indicated
in section 3.8, dogs should not be younger than the minimum age recommended for
the other Nobivac vaccine.
Unvaccinated dogs should receive one dose at least 3 weeks prior to the period of
anticipated risk, e.g. temporary kennelling, in order to get protection for both vaccine
agents. In order to get protection for unvaccinated dogs
should receive one dose at least 72 hours prior to the period of anticipated risk (see
also section 3.5 ‘Special precautions for use’).
Revaccinate annually.
None.
Dogs:
Very common
(>1 animal / 10 animals treated):
Nasal discharge
.
Ocular discharge
.
Common
(1 to 10 animals / 100 animals
reacted):
Sneezing
, cough
.Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Wheezing
. Lethargy. Vomiting.
Hypersensitivity reaction, anaphylactic-type
reaction
.
Immune mediated haemolytic anaemia,
immune mediated thrombocytopenia, immune
mediated polyarthritis.
Particularly observed in very young susceptible puppies. Signs are generally mild
and transient, but in occasional cases may persist for up to four weeks. In animals,
which show more severe signs, appropriate antibiotic treatment may be indicated.
Such reaction may evolve to a more severe condition, which may be life-
threatening. If such reaction occurs, appropriate treatment should be administered
without delay.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.
Vaccinate healthy animals only.

Special precautions for safe use in the target species:
Vaccinated dogs may excrete the Bordetella bronchiseptica vaccine strain up to 6
weeks and the canine parainfluenza vaccine strain up to a few days following
vaccination. During this time, the contact of immunosuppressed and unvaccinated
dogs with vaccinated dogs should be avoided.
Immunosuppressive medication may impair the development of active immunity and
may increase the chance of adverse effects caused by the live vaccine strains.
Cats, pigs and unvaccinated dogs may react to the vaccine strains with mild and
transient respiratory signs. Other animals, like rabbits and small rodents have not
been tested.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Immunocompromised persons are advised to avoid contact with the vaccine and
vaccinated animals up to 6 weeks after vaccination.
Disinfect hands and equipment after use.
Special precautions for the protection of the environment:
Not applicable.
Do not administer in conjunction with other intranasal treatments or during antibiotic
treatment.
Safety and efficacy data are available which demonstrate that this vaccine can be
administered on the
same day, but not mixed, with the live vaccines of the Nobivac series against canine
distemper, canine
contagious hepatitis caused by canine adenovirus type 1, canine parvovirus disease
(based on strain
154) and respiratory disease caused by canine adenovirus type 2, where authorised,
and inactivated
vaccines of the Nobivac series against canine leptospirosis caused by all or some of
the following
serovars: L. interrogans serogroup Canicola serovar Canicola, L. interrogans
serogroup
Icterohaemorrhagiae serovar Copenhageni, L. interrogans serogroup Australis
serovar Bratislava, and
L. kirschneri
Safety data are available which demonstrate that this vaccine can be administered
on the same day but
not mixed with the bivalent puppy vaccine of the Nobivac series that contains canine
parvovirus strain
630a. Efficacy of this vaccine after concurrent use has not been tested. Therefore,
while safety of concurrent use has been demonstrated, the veterinarian should take
this into account when deciding to
administer the products at the same time.
In very rare cases a transient acute hypersensitivity reaction may occur when this
product is used with
other vaccines.
No information is available on the safety and efficacy of this vaccine when used with
any other veterinary medicinal product except the products mentioned above. A
decision to use this vaccine before or after any other veterinary medicinal product
therefore needs to be made on a case by case basis.
In case antibiotics are administered within one week after vaccination, the
vaccination should be repeated after the antibiotic treatment is finished.
Store and transport refrigerated (2 °C – 8 °C).
Do not freeze. Protect from light.
Not applicable.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.

Medication costs adding up?

Pet insurance can cover prescription medications. Find the right policy for your pet.

Compare insurance

Find cheaper vets near you

Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.